DaewonPharmaceutical Launches Topical ‘Newvein’ Following Oral ‘Newvein’… Expanding Its Line of Products for Edema Management
Launch of Two New Face and Body Creams… Targeting the Pharmacy-Exclusive Cosmetics Market
Contains Troxerutin… Improvement in Skin Swelling Confirmed After 4 Weeks of Use
[Edaily Reporter NA EUN-KYUNG ] DaewonPharmaceutical(003220)has launched “Newve Line,” a topical cosmetic for managing swelling, following its oral venous circulation-improving medication “Newvein.” The company plans to expand its presence in the pharmacy-based swelling management market by offering a product lineup that spans both over-the-counter medications and cosmetics.
DaewonPharmaceutical announced on the 18th that it has launched two products in the “Newve Line” series, a pharmacy-exclusive line of cosmetics designed to manage skin swelling around the eyes, on the face, and on the legs. The new products consist of the “Newve Line Slim Fit Eye & Face Cream” and the “Newve Line Slim Fit Body Cream.”
DaewonPharmaceutical’s two newly launched pharmacy-exclusive “Newbeline” swelling management cosmetics. From left: “Newbeline Slim Fit Eye & Face Cream” and “Newbeline Slim Fit Body Cream.” (Photo courtesy of DaewonPharmaceutical)
Both products contain five common ingredients: troxerutin, vitamin K, bromelain, escin, and magnesium. Troxerutin is a semi-synthetic derivative of rutin—a flavonoid derived from the pagoda tree—and is used in products designed to improve venous circulation.
The facial product comes in a 30 mL size and is designed to address puffiness around the eyes and on the face. It is a dual-functional cosmetic that combines skin-brightening and wrinkle-reducing effects, containing niacinamide and adenosine. It features a metal tip for easy application to narrow areas such as the eye contour.
The 150 mL body cream is suitable for use on large areas such as the calves and arms. It is designed with a gua sha-style applicator attached, allowing users to massage the skin while applying the cream.
According to DaewonPharmaceutical, in human application tests conducted for each product, after four weeks of use, the facial cream showed a 20.63% improvement in the temporary skin swelling index compared to before use, while the body cream showed a 7.33% improvement in the calf swelling index. However, specific test conditions—such as the number of test subjects and evaluation methods—were not disclosed.
With this launch, DaewonPharmaceutical has expanded its product lineup for swelling management by adding cosmetics to its existing over-the-counter (OTC) medication, “Newvein Solution.” Newvein Solution is an oral OTC medication containing 3,500 mg of troxerutin, used to treat symptoms such as heaviness and pain in the legs, restless legs syndrome, and hemorrhoids caused by venous and lymphatic circulation disorders.
While Newvein Liquid is a medication designed to alleviate symptoms caused by venous and lymphatic circulation disorders, Newve Line is a cosmetic product intended to manage temporary skin swelling on the face and body. DaewonPharmaceutical plans to address the diverse needs of consumers visiting pharmacies through these two product lines.
A DaewonPharmaceutical official stated, “Newve Line is a product designed for consumers who wish to manage facial and body swelling as part of their daily routine,” adding, “We will provide pharmacy customers with a new option for managing swelling, featuring a formulation tailored to the specific characteristics of each body area and a convenient applicator.”
“The bond market should be a universal channel for corporate financing, but right now it’s like an exclusive social club.”This was the point raised by an advisory committee member during a meeting hel…
KYOCHON FOOD&BEVERAGE, operator of the Kyochon Chicken franchise, is expanding its sales channels for traditional Korean liquor by introducing its premium makgeolli, “Eunhwasu: A Night of Stargazing 1…
SillaJen, Inc.(215600)The company is receiving government support for the development of “SJ-650,” a next-generation anticancer viral therapy administered via intravenous injection. It plans to accele…